NEWS AND HIGHLIGHTS
SEED in
the Spotlight
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Press Release
SEED Therapeutics Doses First Patient in Phase 1 Trial of ST-01156, a Molecular Glue Degrader Targeting RBM39
January 9, 2026

Press Release
SEED Therapeutics Doses First Patient in Phase 1 Trial of ST-01156, a Molecular Glue Degrader Targeting RBM39
January 9, 2026

Press Release
SEED Therapeutics Doses First Patient in Phase 1 Trial of ST-01156, a Molecular Glue Degrader Targeting RBM39
January 9, 2026

Presentations
Corporate Presentation: Transforming Undruggable Targets into Therapeutics
January 9, 2026

Presentations
Corporate Presentation: Transforming Undruggable Targets into Therapeutics
January 9, 2026

Presentations
Corporate Presentation: Transforming Undruggable Targets into Therapeutics
January 9, 2026

Press Release
SEED Therapeutics Receives IND Clearance from China’s NMPA for ST-01156
November 12, 2025

Press Release
SEED Therapeutics Receives IND Clearance from China’s NMPA for ST-01156
November 12, 2025

Press Release
SEED Therapeutics Receives IND Clearance from China’s NMPA for ST-01156
November 12, 2025

Press Release
20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation
September 9, 2025

Press Release
20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation
September 9, 2025

Press Release
20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation
September 9, 2025

Press Release
SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
August 14, 2025

Press Release
SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
August 14, 2025

Press Release
SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
August 14, 2025

Press Release
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
June 9, 2025

Press Release
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
June 9, 2025

Press Release
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
June 9, 2025

Press Release
SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
May 5, 2025

Press Release
SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
May 5, 2025

Press Release
SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
May 5, 2025

Presentations
American Association for Cancer Research 2025 Poster – Targeting Ewing Sarcoma with A Novel RBM39 Degrader
May 1, 2025

Presentations
American Association for Cancer Research 2025 Poster – Targeting Ewing Sarcoma with A Novel RBM39 Degrader
May 1, 2025

Presentations
American Association for Cancer Research 2025 Poster – Targeting Ewing Sarcoma with A Novel RBM39 Degrader
May 1, 2025

Press Release
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
April 24, 2025

Press Release
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
April 24, 2025

Press Release
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
April 24, 2025

Publications
SEED AACR 2025 Presentation: Liu F. et al. Targeting Ewing Sarcoma with A Novel RBM39 Degrader: DNA Damage Repair Pathway Effects (Abstract 1556)
April 1, 2025

Publications
SEED AACR 2025 Presentation: Liu F. et al. Targeting Ewing Sarcoma with A Novel RBM39 Degrader: DNA Damage Repair Pathway Effects (Abstract 1556)
April 1, 2025

Publications
SEED AACR 2025 Presentation: Liu F. et al. Targeting Ewing Sarcoma with A Novel RBM39 Degrader: DNA Damage Repair Pathway Effects (Abstract 1556)
April 1, 2025

Publications
RBM39 Functions as a Potential Oncogene Through the NF-κB Signaling Pathway in Colorectal Cancer Cells
March 29, 2025

Publications
RBM39 Functions as a Potential Oncogene Through the NF-κB Signaling Pathway in Colorectal Cancer Cells
March 29, 2025

Publications
RBM39 Functions as a Potential Oncogene Through the NF-κB Signaling Pathway in Colorectal Cancer Cells
March 29, 2025

Press Release
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
January 28, 2025

Press Release
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
January 28, 2025

Press Release
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
January 28, 2025

Press Release
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024

Press Release
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024

Press Release
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024

Press Release
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
August 11, 2024

Press Release
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
August 11, 2024

Press Release
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
August 11, 2024

Press Release
SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology
March 6, 2024

Press Release
SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology
March 6, 2024

Press Release
SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology
March 6, 2024

Press Release
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
October 26, 2023

Press Release
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
October 26, 2023

Press Release
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
October 26, 2023

Press Release
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member
October 23, 2023

Press Release
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member
October 23, 2023

Press Release
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member
October 23, 2023

Press Release
Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
June 23, 2023

Press Release
Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
June 23, 2023

Press Release
Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
June 23, 2023

Publications
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
June 12, 2023

Publications
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
June 12, 2023

Publications
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
June 12, 2023

Publications
Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker
August 21, 2022

Publications
Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker
August 21, 2022

Publications
Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker
August 21, 2022

Press Release
Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania
July 1, 2022

Press Release
Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania
July 1, 2022

Press Release
Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania
July 1, 2022

Press Release
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
November 13, 2020

Press Release
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
November 13, 2020

Press Release
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
November 13, 2020

Press Release
BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform
August 7, 2020

Press Release
BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform
August 7, 2020

Press Release
BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform
August 7, 2020

Publications
Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade
November 12, 1999

Publications
Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade
November 12, 1999

Publications
Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade
November 12, 1999

Publications
Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor
August 4, 1994

Publications
Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor
August 4, 1994

Publications
Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor
August 4, 1994

Publications
Proposed role of ATP in protein breakdown: Conjugation of proteins with multiple chains of the polypeptide of ATP-dependent proteolysis
April 1, 1980

Publications
Proposed role of ATP in protein breakdown: Conjugation of proteins with multiple chains of the polypeptide of ATP-dependent proteolysis
April 1, 1980

Publications
Proposed role of ATP in protein breakdown: Conjugation of proteins with multiple chains of the polypeptide of ATP-dependent proteolysis
April 1, 1980





